Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody (IgG4 kappa) that targets the programmed death-1 (PD-1) receptor on T-cells. It blocks PD-1 interaction with its ligands (PD-L1 and PD-L2), enhancing immune response against tumor cells. Approved for treatment of various cancers including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and more. It is grouped under the following drug class(es): Antineoplastic agents, Biologics, Checkpoint inhibitors and Monoclonal antibodies. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Lambrolizumab and Keytruda. Its PubChem CID is 168009853.

CAS No 1374853-91-4
Molecular Formula C85H170N4OS
Molecular Weight 1296.4 g/mol
Synonyms 1-butyl-4-propylpiperazine;ethane;1-[hex-5-enyl(2-methyltetradecyl)amino]tetradecan-2-ol;3-[2-methylhexadeca-8,10-dienyl(2-methylhexadeca-9,11-dienyl)amino]propane-1-thiol

Frequently Asked Questions